Cargando…

Effects of Natalizumab Treatment on Foxp3+ T Regulatory Cells

BACKGROUND: Natalizumab, a monoclonal humanized antibody targeting the alpha-4 chain of very late activation antigen 4 (VLA-4) exerts impressive therapeutic effects in patients with relapsing-remitting multiple sclerosis. Our objective was to study impacts of Natalizumab therapy on Foxp3+ T regulato...

Descripción completa

Detalles Bibliográficos
Autores principales:	Stenner, Max-Philipp, Waschbisch, Anne, Buck, Dorothea, Doerck, Sebastian, Einsele, Hermann, Toyka, Klaus V., Wiendl, Heinz
Formato:	Texto
Lenguaje:	English
Publicado:	Public Library of Science 2008
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2553177/ https://www.ncbi.nlm.nih.gov/pubmed/18836525 http://dx.doi.org/10.1371/journal.pone.0003319

Ejemplares similares

Correction: Effects of Natalizumab Treatment on Foxp3+ T Regulatory Cells
por: Stenner, Max-Philipp, et al.
Publicado: (2010)

Neuromyelitis optica presenting with relapses under treatment with natalizumab: a case report
por: Lee, De-Hyung, et al.
Publicado: (2014)

Immunological and clinical consequences of splenectomy in a multiple sclerosis patient treated with natalizumab
por: Lee, De-Hyung, et al.
Publicado: (2013)

Clinical effects of natalizumab on multiple sclerosis appear early in treatment course
por: Kappos, Ludwig, et al.
Publicado: (2013)

Frequency of Regulatory T Cells is Not Affected by Transient B Cell Depletion Using Anti-CD20 Antibodies in Rheumatoid Arthritis
por: Feuchtenberger, Martin, et al.
Publicado: (2008)

Distinct and complementary roles for Aspergillus fumigatus-specific Tr1 and Foxp3(+) regulatory T cells in humans and mice
por: Bedke, Tanja, et al.
Publicado: (2014)

Temporal Pattern of ICAM-I Mediated Regulatory T Cell Recruitment to Sites of Inflammation in Adoptive Transfer Model of Multiple Sclerosis
por: Doerck, Sebastian, et al.
Publicado: (2010)

Efficacy and safety of natalizumab in multiple sclerosis: interim observational programme results
por: Butzkueven, Helmut, et al.
Publicado: (2014)

FoxP3+ Regulatory T Cells Determine Disease Severity in Rodent Models of Inflammatory Neuropathies
por: Meyer zu Hörste, Gerd, et al.
Publicado: (2014)

Therapy with natalizumab is associated with high JCV seroconversion and rising JCV index values
por: Schwab, Nicholas, et al.
Publicado: (2016)

α4-integrin receptor desaturation and disease activity return after natalizumab cessation
por: Derfuss, Tobias, et al.
Publicado: (2017)

Switching from natalizumab to fingolimod: A randomized, placebo-controlled study in RRMS
por: Kappos, Ludwig, et al.
Publicado: (2015)

Comparative efficacy of switching to natalizumab in active multiple sclerosis
por: Spelman, Timothy, et al.
Publicado: (2015)

Natalizumab in the treatment of Crohn’s disease
por: Guagnozzi, Danila, et al.
Publicado: (2008)

Natalizumab in the treatment of multiple sclerosis
por: Brown, Brandon A
Publicado: (2009)

Pathology of immune reconstitution inflammatory syndrome in multiple sclerosis with natalizumab-associated progressive multifocal leukoencephalopathy
por: Metz, Imke, et al.
Publicado: (2011)

Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP)
por: Butzkueven, Helmut, et al.
Publicado: (2020)

Natalizumab for the treatment of relapsing multiple sclerosis
por: Rudick, Richard A, et al.
Publicado: (2008)

Pulmonary eosinophilia associated to treatment with natalizumab
por: Curto, Elena, et al.
Publicado: (2016)

Treatment of natalizumab‐associated PML with filgrastim
por: Stefoski, Dusan, et al.
Publicado: (2019)

Efficacy and Safety of Proposed Biosimilar Natalizumab (PB006) in Patients With Relapsing-Remitting Multiple Sclerosis: The Antelope Phase 3 Randomized Clinical Trial
por: Hemmer, Bernhard, et al.
Publicado: (2023)

Enhanced pathogenicity of Th17 cells due to natalizumab treatment: Implications for MS disease rebound
por: Janoschka, Claudia, et al.
Publicado: (2022)

Foxp3(+) Regulatory T Cells in Bone and Hematopoietic Homeostasis
por: Fischer, Luise, et al.
Publicado: (2019)

Experiences in treatment of multiple sclerosis with natalizumab from a real-life cohort over 15 years
por: Auer, Michael, et al.
Publicado: (2021)

Natalizumab-induced pneumonitis
por: Kaninia, Stefania, et al.
Publicado: (2021)

Changes in JC Virus-Specific T Cell Responses during Natalizumab Treatment and in Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
por: Perkins, Molly R., et al.
Publicado: (2012)

Time-resolved transcriptome and proteome landscape of human regulatory T cell (Treg) differentiation reveals novel regulators of FOXP3
por: Schmidt, Angelika, et al.
Publicado: (2018)

Natalizumab Treatment of Relapsing Remitting Multiple Sclerosis Has No Long-Term Effects on the Proportion of Circulating Regulatory T Cells
por: Tanasescu, Radu, et al.
Publicado: (2023)

CD4(+ )CD25(+ )FoxP3(+ )regulatory T cells suppress cytotoxicity of CD8(+ )effector T cells: implications for their capacity to limit inflammatory central nervous system damage at the parenchymal level
por: Göbel, Kerstin, et al.
Publicado: (2012)

Human FOXP3(+) T regulatory cell heterogeneity
por: Mohr, Audrey, et al.
Publicado: (2018)

Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatment
por: Vollmer, Brandi L., et al.
Publicado: (2018)

Risk Acceptance in Multiple Sclerosis Patients on Natalizumab Treatment
por: Tur, Carmen, et al.
Publicado: (2013)

The role of natalizumab in the treatment of multiple sclerosis: benefits and risks
por: Singer, Barry A.
Publicado: (2017)

Interferons and Natalizumab for Multiple Sclerosis
por: Clar, Christine, et al.
Publicado: (2008)

Immune Cell Profiling During Switching from Natalizumab to Fingolimod Reveals Differential Effects on Systemic Immune-Regulatory Networks and on Trafficking of Non-T Cell Populations into the Cerebrospinal Fluid—Results from the ToFingo Successor Study
por: Lohmann, Lisa, et al.
Publicado: (2018)

The use of natalizumab for multiple sclerosis
por: Brandstadter, Rachel, et al.
Publicado: (2017)

Natalizumab Rebound in Multiple Sclerosis
por: Lee, Joshua D., et al.
Publicado: (2021)

The majority of natalizumab-treated MS patients have high natalizumab concentrations at time of re-dosing
por: van Kempen, Zoé LE, et al.
Publicado: (2017)

Assessment of immune functions and MRI disease activity in relapsing-remitting multiple sclerosis patients switching from natalizumab to fingolimod (ToFingo-Successor)
por: Klotz, Luisa, et al.
Publicado: (2015)

Selective depletion of Foxp3(+) regulatory T cells induces a scurfy-like disease
por: Lahl, Katharina, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_vsa167rs475kgpusrm9jugd0pi